Identification of Potent Reverse Indazole Inhibitors for HPK1.
暂无分享,去创建一个
X. Fradera | Haiyan Xu | M. Bittinger | J. Methot | C. Lesburg | P. Siliphaivanh | J. Miller | A. Pasternak | Ping Liu | J. Piesvaux | Shuhei Kawamura | Zangwei Xu | Brian M. Lacey | Dustin M. Smith | Elsie C. Yu
[1] S. Sawasdikosol,et al. A perspective on HPK1 as a novel immuno-oncology drug target , 2020, eLife.
[2] I. Kariv,et al. Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors , 2020, SLAS discovery : advancing life sciences R & D.
[3] D. Dimitrov,et al. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. , 2020, Cancer cell.
[4] C. Raab,et al. Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization. , 2020, Journal of medicinal chemistry.
[5] M. Lenardo,et al. A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.
[6] J. Hunt,et al. Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance , 2019, PloS one.
[7] BinQing Wei,et al. Hematopoietic Progenitor Kinase-1 Structure in a Domain-Swapped Dimer. , 2019, Structure.
[8] J. Sedelmeier,et al. Evolution of Small Molecule Kinase Drugs. , 2018, ACS medicinal chemistry letters.
[9] K. Duffy,et al. CHAPTER 12:Kinase Inhibition for Immuno-oncology , 2018 .
[10] I. Mellman,et al. The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function. , 2018, Cell reports.
[11] A. Su,et al. A genome-wide survey of mutations in the Jurkat cell line , 2017, bioRxiv.
[12] S. Sawasdikosol,et al. HPK1 as a novel target for cancer immunotherapy , 2012, Immunologic research.
[13] E. Casale,et al. Through the "gatekeeper door": exploiting the active kinase conformation. , 2010, Journal of medicinal chemistry.
[14] H. Yee,et al. Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response , 2009, Cancer Immunology, Immunotherapy.
[15] T. Tan,et al. Functional interactions of HPK1 with adaptor proteins , 2005, Journal of cellular biochemistry.
[16] S. Sawasdikosol,et al. Hematopoietic progenitor kinase 1 (HPK1) negatively regulates prostaglandin E2-induced fos gene transcription. , 2003, Blood.
[17] M. C. Hu,et al. Involvement of Hematopoietic Progenitor Kinase 1 in T Cell Receptor Signaling* , 2001, The Journal of Biological Chemistry.
[18] P. Mackenzie,et al. Structural and functional studies of UDP-glucuronosyltransferases. , 1999, Drug metabolism reviews.
[19] T. Tan,et al. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell–mediated immune responses , 2007, Nature Immunology.